These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 27622508)

  • 1. Ezrin Is Associated with Disease Progression in Ovarian Carcinoma.
    Horwitz V; Davidson B; Stern D; Tropé CG; Tavor Re'em T; Reich R
    PLoS One; 2016; 11(9):e0162502. PubMed ID: 27622508
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ezrin and BCAR1/p130Cas mediate breast cancer growth as 3-D spheroids.
    Konstantinovsky S; Davidson B; Reich R
    Clin Exp Metastasis; 2012 Aug; 29(6):527-40. PubMed ID: 22476538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SCARA3 mRNA is overexpressed in ovarian carcinoma compared with breast carcinoma effusions.
    Bock AJ; Nymoen DA; Brenne K; Kærn J; Davidson B
    Hum Pathol; 2012 May; 43(5):669-74. PubMed ID: 21855113
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proton magnetic resonance metabolomic characterization of ovarian serous carcinoma effusions: chemotherapy-related effects and comparison with malignant mesothelioma and breast carcinoma.
    Vettukattil R; Hetland TE; Flørenes VA; Kærn J; Davidson B; Bathen TF
    Hum Pathol; 2013 Sep; 44(9):1859-66. PubMed ID: 23656974
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Argonaute, Dicer, and Drosha are up-regulated along tumor progression in serous ovarian carcinoma.
    Vaksman O; Hetland TE; Trope' CG; Reich R; Davidson B
    Hum Pathol; 2012 Nov; 43(11):2062-9. PubMed ID: 22647351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MUC4 is upregulated in ovarian carcinoma effusions and differentiates carcinoma cells from mesothelial cells.
    Davidson B; Baekelandt M; Shih IeM
    Diagn Cytopathol; 2007 Dec; 35(12):756-60. PubMed ID: 18008338
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ets-1 mRNA expression in effusions of serous ovarian carcinoma patients is a marker of poor outcome.
    Davidson B; Risberg B; Goldberg I; Nesland JM; Berner A; Tropé CG; Kristensen GB; Bryne M; Reich R
    Am J Surg Pathol; 2001 Dec; 25(12):1493-500. PubMed ID: 11717538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression levels of the nerve growth factor receptors TrkA and p75 in effusions and solid tumors of serous ovarian carcinoma patients.
    Davidson B; Lazarovici P; Ezersky A; Nesland JM; Berner A; Risberg B; Tropé CG; Kristensen GB; Goscinski M; van de Putte G; Reich R
    Clin Cancer Res; 2001 Nov; 7(11):3457-64. PubMed ID: 11705863
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Calreticulin expression is reduced in high-grade ovarian serous carcinoma effusions compared with primary tumors and solid metastases.
    Vaksman O; Davidson B; Tropé C; Reich R
    Hum Pathol; 2013 Dec; 44(12):2677-83. PubMed ID: 24060004
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HMGA2 protein expression in ovarian serous carcinoma effusions, primary tumors, and solid metastases.
    Hetland TE; Holth A; Kærn J; Flørenes VA; Tropé CG; Davidson B
    Virchows Arch; 2012 May; 460(5):505-13. PubMed ID: 22476403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EMMPRIN (extracellular matrix metalloproteinase inducer) is a novel marker of poor outcome in serous ovarian carcinoma.
    Davidson B; Goldberg I; Berner A; Kristensen GB; Reich R
    Clin Exp Metastasis; 2003; 20(2):161-9. PubMed ID: 12705637
    [TBL] [Abstract][Full Text] [Related]  

  • 12. VICKZ2 protein expression in ovarian serous carcinoma effusions is associated with poor survival.
    Davidson B; Rosenfeld YB; Holth A; Hellesylt E; Tropé CG; Reich R; Yisraeli JK
    Hum Pathol; 2014 Jul; 45(7):1520-8. PubMed ID: 24814803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interleukin-8 and vascular endothelial growth factor mRNA and protein levels are down-regulated in ovarian carcinoma cells in serous effusions.
    Davidson B; Reich R; Kopolovic J; Berner A; Nesland JM; Kristensen GB; Tropé CG; Bryne M; Risberg B; van de Putte G; Goldberg I
    Clin Exp Metastasis; 2002; 19(2):135-44. PubMed ID: 11964077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Death domain-associated protein (DAXX) expression is associated with poor survival in metastatic high-grade serous carcinoma.
    Davidson B; McFadden E; Holth A; Brunetti M; Flørenes VA
    Virchows Arch; 2020 Dec; 477(6):857-864. PubMed ID: 32533344
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of the Ets transcription factor EHF in serous ovarian carcinoma effusions is a marker of poor survival.
    Brenne K; Nymoen DA; Hetland TE; Trope' CG; Davidson B
    Hum Pathol; 2012 Apr; 43(4):496-505. PubMed ID: 21855111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aurora B expression in metastatic effusions from advanced-stage ovarian serous carcinoma is predictive of intrinsic chemotherapy resistance.
    Hetland TE; Nymoen DA; Holth A; Brusegard K; Flørenes VA; Kærn J; Tropé CG; Davidson B
    Hum Pathol; 2013 May; 44(5):777-85. PubMed ID: 23114921
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of the chromatin remodeling factor Rsf-1 is upregulated in ovarian carcinoma effusions and predicts poor survival.
    Davidson B; Trope' CG; Wang TL; Shih IeM
    Gynecol Oncol; 2006 Dec; 103(3):814-9. PubMed ID: 16844205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Defining a prognostic marker panel for patients with ovarian serous carcinoma effusion.
    Davidson B; Smith Y; Nesland JM; Kærn J; Reich R; Tropè CG
    Hum Pathol; 2013 Nov; 44(11):2449-60. PubMed ID: 24011953
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Migfilin, α-parvin and β-parvin are differentially expressed in ovarian serous carcinoma effusions, primary tumors and solid metastases.
    Davidson B; Holth A; Nguyen MT; Tropé CG; Wu C
    Gynecol Oncol; 2013 Feb; 128(2):364-70. PubMed ID: 23099104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Netrin-4 is upregulated in breast carcinoma effusions compared to corresponding solid tumors.
    Yuan Y; Leszczynska M; Konstantinovsky S; Tropé CG; Reich R; Davidson B
    Diagn Cytopathol; 2011 Aug; 39(8):562-6. PubMed ID: 20730893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.